Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study.

Front Oncol · 2025 · PMC12104222 · PMID 40421088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

found marginally significant OS benefit of allo-HSCT in the analysis of the overall study patients, whereas not OS benefit of allo-HSCT among patients who achieved CR after blinatumomab was observed ( 30 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.